Publications
Ko AH, Tempero MA. Treatment of metastatic pancreatic cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2005. PMID: 16194454
Ko AH, Tempero MA. Treatment of metastatic pancreatic cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2005. PMID: 16194454
Whisenant J, Bergsland E. Anti-angiogenic strategies in gastrointestinal malignancies. Current treatment options in oncology. 2005. PMID: 16107244
McCabe N, Lord CJ, Tutt AN, Martin NM, Smith GC, Ashworth A. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency. Cancer biology & therapy. 2005. PMID: 16251802
Howard B, Panchal H, McCarthy A, Ashworth A. Identification of the scaramanga gene implicates Neuregulin3 in mammary gland specification. Genes & development. 2005. PMID: 16140987
Reis-Filho JS, Simpson PT, Jones C, Steele D, Mackay A, Iravani M, Fenwick K, Valgeirsson H, Lambros M, Ashworth A, Palacios J, Schmitt F, Lakhani SR. Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. The Journal of pathology. 2005. PMID: 15957152
Garcia JA, Weinberg V, Small EJ. Prior estrogen therapy as a predictor of response to subsequent estramustine-based chemotherapy in patients with androgen-independent prostate cancer. Clinical prostate cancer. 2005. PMID: 16197612
Taron M, Ichinose Y, Rosell R, Mok T, Massuti B, Zamora L, Mate JL, Manegold C, Ono M, Queralt C, Jahan T, Sanchez JJ, Sanchez-Ronco M, Hsue V, Jablons D, Sanchez JM, Moran T. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005. PMID: 16115929
Bhatt AS, Erdjument-Bromage H, Tempst P, Craik CS, Moasser MM. Adhesion signaling by a novel mitotic substrate of src kinases. Oncogene. 2005. PMID: 16007225
Yue N, Heron DE, Komanduri K, Huq MS. Prescription dose in permanent (131)Cs seed prostate implants. Medical physics. 2005. PMID: 16193779
Rubenstein JL, Treseler P, O'Brien JM. Pathology and genetics of primary central nervous system and intraocular lymphoma. Hematology/oncology clinics of North America. 2005. PMID: 16083831
Ashworth A. Oh what a tangled web it weaves: BRCA1 and DNA decatenation. Cancer cell. 2005. PMID: 16098462
Turner N, Tutt A, Ashworth A. Targeting the DNA repair defect of BRCA tumours. Current opinion in pharmacology. 2005. PMID: 15955736
Huang FW, Pinkus JL, Pinkus GS, Fleming MD, Andrews NC. A mouse model of juvenile hemochromatosis. The Journal of clinical investigation. 2005. PMID: 16075059
Taplin ME, George DJ, Halabi S, Sanford B, Febbo PG, Hennessy KT, Mihos CG, Vogelzang NJ, Small EJ, Kantoff PW. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Urology. 2005. PMID: 16098367
Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. British journal of cancer. 2005. PMID: 15999098
Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. British journal of cancer. 2005. PMID: 15999098
Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. British journal of cancer. 2005. PMID: 15999098
Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA. Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer. British journal of cancer. 2005. PMID: 15999098
Liu G, Rugo HS, Wilding G, McShane TM, Evelhoch JL, Ng C, Jackson E, Kelcz F, Yeh BM, Lee FT, Charnsangavej C, Park JW, Ashton EA, Steinfeldt HM, Pithavala YK, Reich SD, Herbst RS. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005. PMID: 16027440